PLS Prognosis & Life Expectancy

If you have just received a PLS diagnosis, the question you most need answered is probably this one: how long do I have, and what will my life look like? The honest answer — supported by research — is more encouraging than most people expect.

The short answer

Most people with PLS live for a long time after diagnosis. Life expectancy in PLS approaches near-normal. PLS is not typically fatal in the way ALS is — the respiratory failure that ends most ALS lives within two to five years is uncommon in PLS. The disease progresses, and over years and decades it creates real disability. But the trajectory of PLS is measured in years and decades, not months.

That is not a platitude. It is what the research shows.

Life expectancy: what the data show

The Scirocco 2025 JNNP study

The most detailed survival data available for PLS comes from a 2025 study published in the Journal of Neurology, Neurosurgery and Psychiatry, following 52 PLS patients longitudinally from symptom onset. The key findings:

Median survival from symptom onset: 23.1 years
Median age at death: 79.5 years
Population reference life expectancy for comparison: 81.9 years
Only 10% of patients required a gastrostomy (feeding tube)
Only 6% required non-invasive ventilation

A median survival from symptom onset of 23 years means that half the people in this study lived more than 23 years after their first symptoms appeared. A median age at death of 79.5 means those deaths occurred less than three years earlier than the general population average.

The near-absence of gastrostomy and ventilation requirements is clinically significant. These two interventions mark major milestones of disease progression in ALS and are required by the majority of ALS patients. In PLS, they remain uncommon throughout the disease course, reflecting how intact bulbar and respiratory function tends to remain.

The Gordon et al. 2006 Neurology study

The foundational natural history study for PLS was published by Gordon and colleagues in Neurology in 2006 — the first large prospective cohort study of PLS patients. It established the clinical benchmarks still used to distinguish PLS from ALS and to describe PLS progression. Gordon et al. 2006 documented the slowly progressive upper motor neuron course that characterizes PLS, the rarity of significant bulbar and respiratory involvement, and the markedly better survival compared to ALS.

Earlier estimates and context

Some older sources describe PLS life expectancy in a range of roughly 7–20 years from symptom onset. These figures predate the 2020 consensus criteria and were often based on cohorts that included patients who later converted to ALS — which would artificially reduce the average survival. Studies restricted to patients who maintained a pure upper motor neuron course show longer survival, consistent with the 23-year median in the 2025 data.

Rate of progression

PLS does progress. Denial of that reality would not serve you. But the rate of progression in PLS is substantially slower than in ALS, and understanding what that means in concrete terms matters.

ALSFRS-R decline

The ALS Functional Rating Scale – Revised (ALSFRS-R) is a 48-point scale measuring functional abilities across speech, swallowing, breathing, hand function, and mobility. It is the standard tool used in motor neuron disease research to measure how quickly function declines.

In ALS, patients typically lose approximately 5 or more points per year on the ALSFRS-R — and often more as the disease accelerates.

In PLS, the NEALS Consortium PLS registry — following 250 patients over 15 years — found an average functional decline of 1.6 points per year on the ALSFRS-R (Scirocco et al., 2025, citing Statland et al.). The 2025 JNNP longitudinal study found a mean annual rate of decline of approximately 1.92 ALSFRS-R points per year.

At 1.6–2 points per year of decline on a 48-point scale, a person starting with full function might expect to retain meaningful independence across most domains for many years. The pace of decline varies between individuals, and the ALSFRS-R captures only part of the functional picture, but this number gives you a concrete frame of reference.

The Mayo Clinic Natural History Study

A prospective multicenter natural history study at Mayo Clinic (with sites in Rochester, MN and Jacksonville, FL) has been tracking PLS patients using the PLS Functional Rating Scale (PLSFRS). Published findings from this study in Annals of Neurology (2026) showed a PLSFRS decline of approximately 0.33 points per month — with the rate steepest in patients with shorter disease duration (under two years from onset). This suggests functional decline may be fastest early in the disease and stabilizes somewhat over time in established PLS.

The study also found that baseline neurofilament light chain (NfL) levels were associated with the rate of PLSFRS decline over one year, suggesting NfL may become a useful prognostic biomarker in PLS.

The PLS Functional Rating Scale

The PLS Functional Rating Scale (PLSFRS) is a disease-specific outcome measure developed for PLS research and increasingly used in clinical settings. Unlike the ALSFRS-R, it was designed specifically for the PLS disease spectrum and its particular pattern of functional impairment — emphasizing spasticity, gait, and upper limb function, where PLS has its greatest impact.

If you are participating in clinical research or being followed at a center with a PLS-specific protocol, you may be assessed with the PLSFRS at each visit. Tracking your score over time gives you and your neurologist a concrete way to measure how quickly (or slowly) things are changing.

What slow progression looks like over decades

Understanding prognosis in PLS means thinking in a longer time frame than most people are initially prepared for. Here is what the research-supported picture tends to look like:

Years 1–5: Gait changes become more noticeable. Most people continue working and living independently, though some begin using a walking aid such as a cane. The diagnostic process is often still ongoing.
Years 5–10: Stiffness and weakness in legs typically increases. Many people begin using a walking frame or rollator. Some transition to a wheelchair for longer distances, while remaining ambulatory at home. Arms may begin to show increased tone and reduced fine motor control.
Years 10–20+: The majority of people with PLS require a wheelchair for most mobility by this stage. Upper limb function continues to decline. Speech remains largely intact in most people — research shows 88% retain serviceable speech. Respiratory function remains good in 96% of patients.

This is not a uniform course. People vary. Some progress faster; some remain stable for long periods. But this general arc — measured in years and decades, with mobility as the primary disability rather than respiratory or bulbar failure — is the typical PLS experience.

Factors that affect outlook

Several factors are associated with prognosis in PLS:

Onset region: Limb-onset PLS (the most common form) tends to have a more gradual course than corticobulbar-onset PLS. Early prominent bulbar involvement may indicate faster functional change in speech and swallowing.
Time to diagnosis: Reaching a definite PLS diagnosis (4+ years of pure upper motor neuron signs) substantially reduces the probability of ALS conversion. The 23% of patients who convert to ALS do so within those first four years; those who remain pure PLS beyond that threshold have a very different long-term outlook.
Biomarkers (emerging): Research from the Mayo Clinic Natural History Study suggests that baseline neurofilament light chain levels may help predict the rate of decline. This is not yet a routine clinical tool but may become one.
Multidisciplinary care: Access to physical therapy, occupational therapy, and speech-language pathology — currently underutilized in PLS — is associated with better functional maintenance. Research found that only 24% of PLS patients were receiving physical therapy, 12% speech therapy, and 8% occupational therapy.

Reframing the diagnosis

The moment of diagnosis is often the worst moment. You have heard the words "motor neuron disease" — words associated in most people's minds with ALS — and whatever comes next in the neurologist's explanation may not fully land. It is worth returning to the data once the shock has settled.

A median age at death of 79.5 years, compared to a population average of 81.9, means most people with PLS lose roughly two years of life expectancy relative to someone without the disease. Those two years come at the end of a life that, for much of its course, remains active and engaged — adapted to the physical limitations PLS creates, but not ended by them.

PLS is a serious disease. It causes real disability that accumulates over years and requires genuine adaptation. But it is not a terminal diagnosis in the timeframe people fear when they first hear it. The research supports a long life — one that will require adjustment, good medical care, and planning, but one that is genuinely available to you.

People who do well with PLS tend to share a few things: they stay connected to specialist care, they stay as physically active as safely possible, they plan ahead for the mobility aids and home adaptations they will eventually need, and they find communities of others who understand what PLS actually means to live with. None of those things require accepting a grim prognosis. They just require taking the long view — which, as the data show, is exactly what PLS asks of you.